

CLAIMS

What is claimed is:

1. 5 1. A method of treating inflammatory in a mammal comprising administering to said mammal a combination of: (i) a standard therapeutic dose of COX2 inhibitors selected from the group consisting of (i) celecoxib (Celebrex[®]) [A], rofecoxib (Vioxx[®]) [B], and other specific COX2 inhibitors [C], (ii) low dose aspirin (70-85 mg), and (iii) antioxidant flavanoids, flavonoids or isoflavones.
- 10 2. The method of claim 1 wherein the combination of (i) and (ii) or (iii) provides improved efficacy or safety effect in tumor growth and metastasis in conjunction with chemotherapy, radiotherapy or tumor surgery.
- 15 3. The method of claim 1, wherein the combination administered is a combination of the COX2 inhibitors, flavanoids, and a low dose aspirin or other antiplatelet agents for the prevention and treatment of various thromboembolic disorders as defined earlier in the background.
- 20 4. The method of claim 1, wherein the combination administered is a combination of the COX2 inhibitors, flavanoids, and a low dose aspirin or other antiplatelet agents for the prevention and treatment of various inflammatory disorders as defined earlier in the background.
- 25 5. The method of claim 1-5, wherein the COX2 inhibitors is compound [A], compound [B] or compound [C] and low dose aspirin of 70-85 mg in an enteric coated formulation. This preferred enteric-coated formulation should allow for improved efficacy and safety.